Cite
HARVARD Citation
Kapelios, C. et al. (2019). Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world. European journal of heart failure. pp. 1383-1397. [Online].